Literature DB >> 21536939

Individualized guidelines: the potential for increasing quality and reducing costs.

David M Eddy1, Joshua Adler, Bradley Patterson, Don Lucas, Kurt A Smith, Macdonald Morris.   

Abstract

BACKGROUND: Current guidelines focus on a particular risk factor and specify criteria for categorizing persons into a small number of treatment groups.
OBJECTIVE: To compare current guidelines with individualized guidelines (that use readily available characteristics from each person to calculate the risk reduction expected from treatment and to identify persons for treatment in ranked order of decreasing expected benefit), in the context of blood pressure management.
DESIGN: Analysis of person-specific, longitudinal data.
SETTING: The ARIC (Atherosclerosis Risk in Communities) Study. PARTICIPANTS: Persons aged 45 to 64 years without preexisting cardiovascular disease who currently do not receive antihypertensive treatment. INTERVENTION: Treatment according to the criteria of the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7 guidelines); individualized guidelines, or treatment in decreasing order of expected benefit; and random care, or treatment of persons selected at random. MEASUREMENTS: Number of myocardial infarctions (MIs) and strokes and medical costs.
RESULTS: Compared with treating people according to random care, individualized guidelines could prevent the same number of MIs and strokes as JNC 7 guidelines at savings that are 67% greater than using JNC 7 guidelines, or it could prevent 43% more MIs and strokes for the same cost as treatment according to JNC 7 guidelines. The superiority of individualized guidelines was not sensitive to a wide range of assumptions about costs, treatment effectiveness, level of risk for cardiovascular disease in the population, or effects on workflow. The degree of superiority was sensitive to the accuracy of the method used to rank patients and to its span (the proportion of the population for whom all of the outcomes of interest can be calculated). LIMITATIONS: Specific results apply to the effects of blood pressure management on MI and stroke in the ARIC Study population. The methods for calculating individual benefits require quantitative evidence about the relationships among risk factors, long-term outcomes, and treatment effects.
CONCLUSION: Use of individualized guidelines can help to increase the quality and reduce the cost of care.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21536939     DOI: 10.7326/0003-4819-154-9-201105030-00008

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  46 in total

Review 1.  What is personalized medicine and what should it replace?

Authors:  David C Whitcomb
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-05-22       Impact factor: 46.802

2.  Personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy.

Authors:  Nicole M Kuderer; Gary H Lyman
Journal:  J Natl Cancer Inst       Date:  2011-06-13       Impact factor: 13.506

3.  Clinical guidelines, the politics of value, and the practice of medicine: physicians at the crossroads.

Authors:  Richard A Cooper; David J Straus
Journal:  J Oncol Pract       Date:  2012-05-29       Impact factor: 3.840

4.  Ethics: Genetic testing for MEN1--whose responsibility?

Authors:  Cornelis J M Lips; Jo W M Höppener
Journal:  Nat Rev Endocrinol       Date:  2012-09-11       Impact factor: 43.330

5.  What Do Patients Want? Patient Preference in Wound Care.

Authors:  Lisa Q Corbett; William J Ennis
Journal:  Adv Wound Care (New Rochelle)       Date:  2014-08-01       Impact factor: 4.730

6.  A clinically guided approach for improving performance measurement for hypertension.

Authors:  Michael A Steinman; Sei J Lee; Carolyn A Peterson; Kathy Z Fung; Mary K Goldstein
Journal:  Med Care       Date:  2012-05       Impact factor: 2.983

7.  Cost-effectiveness of hypertension therapy according to 2014 guidelines.

Authors:  Andrew E Moran; Michelle C Odden; Anusorn Thanataveerat; Keane Y Tzong; Petra W Rasmussen; David Guzman; Lawrence Williams; Kirsten Bibbins-Domingo; Pamela G Coxson; Lee Goldman
Journal:  N Engl J Med       Date:  2015-01-29       Impact factor: 91.245

Review 8.  Cardiovascular risk.

Authors:  Rupert A Payne
Journal:  Br J Clin Pharmacol       Date:  2012-09       Impact factor: 4.335

9.  Using benefit-based tailored treatment to improve the use of antihypertensive medications.

Authors:  Jeremy Sussman; Sandeep Vijan; Rod Hayward
Journal:  Circulation       Date:  2013-11-04       Impact factor: 29.690

10.  Estimating Longitudinal Risks and Benefits From Cardiovascular Preventive Therapies Among Medicare Patients: The Million Hearts Longitudinal ASCVD Risk Assessment Tool: A Special Report From the American Heart Association and American College of Cardiology.

Authors:  Donald M Lloyd-Jones; Mark D Huffman; Kunal N Karmali; Darshak M Sanghavi; Janet S Wright; Colleen Pelser; Martha Gulati; Frederick A Masoudi; David C Goff
Journal:  J Am Coll Cardiol       Date:  2016-11-04       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.